<DOC>
	<DOCNO>NCT00673621</DOCNO>
	<brief_summary>This study compare rate extent absorption TI Inhalation Powder subject asthma subject normal lung function . 24 eligible subject enrol treatment phase trial .</brief_summary>
	<brief_title>A Study Designed Determine Pharmacokinetic Disposition Inhaled Insulin Exposure Same Asthmatics Non-asthmatics</brief_title>
	<detailed_description>Visit 1 screen determine eligibility obtain informed consent . At visit 2 , 3 4 subject inhale 1 dose 45U TI Inhalation Powder . At visit 3 subject inhale 2 puff ( 200mcg ) Albuterol prior dose . Only asthmatic subject undergo visit 4 methacholine challenge test ( MCT ) perform follow inhalation Albuterol administration TI Inhalation Powder . Each visit 's dose occur hyperinsulinemic euglycemic clamp . Visit 5 follow visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<criteria>Non smoke male female subject = 18 = 55 year age BMI = 34 kg/m2 Fasting blood glucose ( FBG ) &lt; 110 mg/dL ( 6.1 mmol/L ) . Written inform consent Asthmatic Subjects : Clinical diagnosis asthma along defined reversibility pre postbronchodilator spirometry . Pulmonary Function Testing Asthmatic subject : FEV1 &gt; 70 % ( NHANES III ) , TLC &gt; 70 % ( ITS ) , Dlco &gt; 80 % ( Miller ) Nonasthmatic healthy subject : FEV1 &gt; 80 % ( NHANES III ) , FEV1/FVC &gt; LLN ( NHANES ) , TLC &gt; 80 % ( ITS ) , Dlco &gt; 80 % ( Miller ) , significant improvement pre postbronchodilator spirometry . Unable and/or unlikely comprehend use investigational device study follow study instruction Change asthma therapeutic regimen Screening visit 5 Exacerbation asthma within 8 week prior Screening History diabetes mellitus Previous exposure inhale insulin product TI inhalation Powder similar formulation Inability perform PFT maneuver meet recommended American Thoracic Society ( ATS ) standard acceptability repeatability criteria Any clinically important pulmonary disease Major organ system diseases include seizure , heart failure , uncontrolled hypertension , cancer within past 5 year , aneurysm , liver disease , anemia autoimmune disorder Clinically significant abnormality screen laboratory evaluation Female subject pregnant , lactating , plan become pregnant clinical trial period practice adequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Asthmatics non-asthmatic male female subject</keyword>
</DOC>